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Abstract 
 
Most of the patients with end-stage renal disease who undergo hemodialysis receive 
erythropoietin (EPO) therapy for anemia treatment. Anemia with EPO deficiency is a common 
complication of chronic kidney disease (CKD). EPO therapy is expected to improve anemia and 
quality of life of patients. This analytic observational study was conducted in a cross-sectional design. 
It aimed to identify the difference in red blood cell profiles, namely hemoglobin (Hb), Mean 
Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), and Mean Corpuscular 
Hemoglobin Concentration (MCHC), and quality of life of CKD patients on EPO and non-EPO 
therapy at PKU Muhammadiyah Hospital in Yogyakarta. The inclusion criteria were PGK ICD N18.9 
outpatients who received hemodialysis therapy at this hospital and were literate, able to understand the 
questionnaire, and willing to be a respondent. The results showed that there was no significant 
difference (p>0,05) between the red blood cells (Hb, MCV, MCH, MCHC) of the EPO and non-EPO 
therapy groups. The correlation between the EPO and the quality of life of patients in all of the 
KDQOL domains was p> 0.05. Aside from the insignificant difference between the EPO and non-EPO 
therapy groups, the research concluded that there was no correlation between either the EPO or the 
non-EPO therapy with the quality of life of hemodialysis patients. 
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INTRODUCTION 
Anemia is prevalent in patients with chronic kidney disease (CKD) who undergo hemodialysis 
therapy. It has been reported in 80-90% of CKD patients. It is associated with Erythropoietin (EPO) 
deficiency due to the inability of the kidneys to produce EPO physiologically (Sari et al., 2014). 
Anemia management in CKD patients mostly relies on the use of EPO (Gombotz, 2012). It is a 
widely accepted treatment, as well as the first-line therapy for anemia in CKD patients (Singh, 2008). 
Although it has many advantages, EPO drug is expensive and, therefore, burdensome for patients who 
must take it (Mikhail et al., 2012).  
In practice, there are two types of treatment for anemia of CKD, namely EPO and non-EPO. 
The later combines folic acid, iron, and vitamin B1. A study by Hidayati et al. (2012) at PKU 
Muhammadiyah Hospital in Yogyakarta shows that erythropoietin alpha is used in 69.05% anemia 
treatment whereas erythropoietin beta in 30.95%. As for the pre-oral adjuvant therapies (82.05%), 
most of them administer the combination of folic acid, iron, and vitamin. Only a few of them use folic 
acid (10.26%) and folic acid-vitamin B complex combination (7.69%).   
Anemia contributes to the reduced quality of life of patients with end-stage kidney disease. Most 
CKD patients on hemodialysis have to receive EPO therapy or take erythropoietin-stimulating agents 
routinely to treat their anemia. Anemia due to EPO deficiency is a common complication of CKD. It 
can be treated with EPO administration, red blood cell transfusion, or the combination of both. 
However, the widely accepted treatment by anemic patients is the administration of EPO. Early studies 
found that EPO reduced the need for red blood cell transfusions and improved quality of life of CKD 
patients compared with no EPO administration.  
This study aimed to determine the differences in the profiles of hemoglobin (Hb), Mean 
Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), and Mean Corpuscular 
Hemoglobin Concentration (MCHC) and the quality of life of CKD patients on either EPO or non-
EPO therapy for their anemia management.  
 
INSTRUMENT AND METHOD 
Instrument 
The instrument used in this study was the Kidney Disease Quality of Life Short Form (KDQOL-
SF
TM
) v. 1.3 published by RAND. This questionnaire was first translated into Indonesian by the UAD 
Language Development Center. The translation process was forward, i.e., from English to Indonesian 
by a translator.  
 
Methods 
This analytical observational study employed a cross-sectional approach. The subjects were 
patients with chronic renal failure on hemodialysis at PKU Muhammadiyah Hospital in Yogyakarta in 
July 2017. They were selected purposively according to the predefined inclusion and exclusion 
criteria. The samples were 87 patients consisting of 78 patients receiving EPO (EPO therapy group) 
and 9 patients receiving non-EPO (non-EPO therapy group).  
The inclusion criteria were: outpatients diagnosed with CKD who underwent treatment at the 
hemodialysis unit of the hospital and were literate, able to understand the questionnaire, and willing to 
participate in the study.  
The research data included Hb, MCH, MCV, and MCHC, as well as the quality of life of CKD 
patients on hemodialysis who suffered from anemia and managed it with erythropoietin therapy. The 
research method involved the design, place, and scope or object of the activities, main materials and 
tools, data collection technique, the operational definition of the research variables, and analysis 
technique. The quality of life was obtained from respondents in July 2017 using the Indonesian version 
of KDQOL-SF
TM
 v.1.3. 
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Data Analysis 
This research performed an independent samples t-test on Hb, MCH, MCV, MCHC, and quality 
of life of the selected patients. It also used a statistical test for comparison of proportions, namely the 
chi-square test, to identify the presence or absence of any differences between the EPO and the non-
EPO therapy groups.  
 
RESULTS AND DISCUSSION 
Hb, MCV, MCH and MCHC Profiles 
Table I presents the mean values of the Hb, MCV, MCH, and MCHC of both EPO and non-
EPO (iron) therapy groups.  
 
Table I. The mean values of the red blood cell profiles of the EPO and the non-EPO therapy 
groups 
Profiles Hb MCV MCH MCHC 
(  + SD) 9.28 ± 1.528 90.06 ± 6.150 29.60±1.998 32.89±0.688 
Independent t–test  
(P-values) 
0.068 0.124 0.164 0.415 
 
The independent samples t-test on the red blood cell profiles (Table I) produced different p-
values for each variable, namely Hb= 0.068, MCV= 0.124, MCH= 0.164, and MCHC= 0.415. These 
figures indicate that there is no significant difference between the red blood cell profiles of the EPO 
and the non-EPO (iron) therapy groups.  
The mean Hb values of the EPO therapy group and the iron therapy group was 9.28 ± 1.528 (p-
value= 0.068), representing an insignificant difference. In other words, the increased Hb levels in both 
therapy groups are not significantly different. Nevertheless, the red blood cell profiles showed that the 
mean Hb level of the EPO therapy group was 1.00 higher than the iron therapy group. Therefore, the 
EPO therapy is better than the iron therapy.  
The same case of insignificant difference between the two groups applied to MCV, MCH, and 
MCHC, which are measures of anemic conditions. MCV is the average volume of erythrocytes. When 
thalassemia and anemia of chronic disease are excluded from the diagnosis, MVC indicates iron-
deficiency anemia. The MVC was within the normal range, i.e., 82-93 femtoliters. The MCH―the 
average amount of hemoglobin (picogram) per erythrocyte―was also normal, i.e., 27-33 
picogram/erythrocyte cell. Furthermore, the MCHC of the groups was also in the normal state, i.e., 
within 33-36%. MCHC describes the average concentration of red blood cells (weight per volume). As 
a conclusion, the MCV, MCH, and MCHC profiles in this study are normal. 
Based on the blood sample data, both EPO therapy and iron therapy did not result in significant 
differences. The use of EPO and iron at PKU Muhammadiyah Hospital in Yogyakarta is according to 
the regulations issued by the Indonesian Nephrology Association (PERNEFRI, 2011). In anemia 
management, the targeted Hb is >10 g/dl. The European Best Practice Guidelines for the management 
of anemia in CKD patients state that the lower limits of normal Hb are 11.5 gr/dl in women and 13.5 
gr/dl in men aged <70 years or 12.0 gr/dl in men aged >70 years (KDIGO, 2012). According to 
PENEFRI (2011), the EPO response is categorized as inadequate if the patient fails to achieve the 
desired or targeted Hb level after receiving EPO for 4-8 weeks. Iron is administered to correct the iron 
stores. After the iron stores are sufficient, iron therapy is continued with EPO therapy. In iron therapy, 
the targets are ferritin >100 μg/L and transferrin saturation >20%. However, this study did not include 
ferritin due to the assumption that all sampled patients suffered from EPO-deficiency anemia.  
The results showed that there was no significant difference between the red blood cell profiles 
of the EPO and the non-EPO therapy groups. Many factors can affect Hb levels aside from the type of 
therapy, e.g., exercise and physical activity. The Hb levels of individuals who routinely exercise are 
slightly increased because tissues or cells require more O2 (oxygen) during physical activities (Bahri et 
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al., 2009 in Saputro and Junaidi, 2015). The other factors that can affect Hb levels and red blood cells 
in a person are food, age, sex, activity, smoking habit, and co-occurring diseases like leukemia, 
thalassemia, and tuberculosis. The food contains nutrients or nutritional components that are used to 
promote the formation of hemoglobin (i.e., Fe or iron and protein). The Hb levels in females are easier 
to drop than in males, especially during menstruation (Curtale et al., 2000 in Saputro and Junaidi, 
2015). The consumption of, for instance, vitamin C can increase iron absorption by up to four times 
(Wirakusumah, 1998). According to Patimah (2007), iron is a precursor that is very necessary for the 
formation of hemoglobin and red blood cells (erythrocytes). Besides, vitamin C is one of the necessary 
antioxidants obtained from outside sources. The oral administration of vitamin C can provide potential 
benefits as it reduces the damages that free radicals cause to the tissues (Khassaf et al., 2003). 
 
Quality of Life 
KDQOL SF-36 consists of 36 questions with eight dimensions, namely: physical function, role 
limitations due to physical problems, role limitations due to emotional problems, social function, 
mental/psychological health, vitality, body pain, and general perception of health. After the mean 
value of each domain had been calculated, this research categorized respondents into three groups, 
namely below, within, and above the average. The more the respondents below the average score in a 
domain, the more difficult the achievement of good quality of life in the said domain (Purwitasari, 
2016). The scores and the number of respondents by domain are presented in Table II.   
Kidney failure deteriorated the physical quality of half of the respondents. The quality of life of 
hemodialysis patients is lower than individuals in general for they tend to experience physical 
suffering and limitations in daily activities (Mailani, 2015). Using the SF-36 questionnaires to obtain 
information from 60 respondents, Senduk et al. (2016) can describe the relationship of anemia and the 
quality of life of CKD patients on hemodialysis. They explain that these patients experience a decrease 
in some scales, including physical functioning, physical limitations, general health, and vitality. CKD 
weakens the physical states and potentially reduces the patient’s motivation. The symptoms of reduced 
physical health status are strongly associated with sleep problems and depression, all of which affect 
the quality of life (Mardyaningsih, 2014). 
 
Table II. The quality of life of the respondents by KDQOL domain 
 
Domains Quality of Life 
Number of 
Respondents 
Domain 1 
(Physical Function) 
<52.4 Low 43 
>52.4 High 50 
Domain 2 
(Physical State) 
<26.1 Low 67 
>26.1 High 26 
Domain 3 
(Body Pain) 
<55.5 Low 38 
>55.5 High 55 
Domain 4 
(General Health) 
<50.7 Low 46 
>50.7 High 47 
Domain 5 
(Mental Health) 
<76.6 Low 45 
>76.6 High 48 
Domain 6 
(Emotional 
Condition) 
<40.5 Low 64 
>40.5 High 29 
Domain 7 
(Social Function) 
<67.5 Low 48 
>67.5 High 45 
Domain 8 
(Vital Function) 
<61.6 Low 47 
>61.6 High 46 
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Hemodialysis patients are also susceptible to emotional problems like stress that is attributable 
to dietary and fluid restrictions, physical limitations, the disease itself, side effects of drugs, and 
dependence on dialysis, all of which decrease the quality of life. Most of the time, they suffer from 
depression and anxiety―psychological disorders―due to uremia symptoms, such as fatigue, sleep 
disorders, decreased appetite, and cognitive impairment. Depression is found in up to 50% of patients 
who have just started dialysis treatment. The symptoms include guilt, despair, irritability, and suicide. 
Patients also feel as if they have become a burden to the family and worried about any disruptions to 
their appearance or body image (Mailani, 2015). 
Table III informs the results of the statistical test for comparison of proportions, i.e., chi-square 
test, on the quality of life of anemic CKD patients in both EPO and non-EPO therapy groups. The test 
results on all domains showed that both therapy groups did not have different quality of life. This 
finding is contrary to Keown et al. (2010), which affirm that EPO therapy can improve the quality of 
life of CKD patients. Factors that influence the quality of life of CKD patients on dialysis include 
decreased physical condition, duration of hemodialysis, compliance with adjuvant therapy, 
complications of CKD disease, and the severity of anemia. Decreased physical condition is a sign of a 
patient’s poor quality of life. It is determined by age and medical history. The older the patient, the 
poorer the physical condition and the lower the energy produced in the body (Purwitasari, 2016). 
 
Table III. The relationship between the administration of erythropoietin 
 and the quality of life of CKD patients by KDQOL domain 
 
Domains Groups 
Quality of Life 
P-values 
Low High 
1 
EPO 
38 45 
0.530 
Non-EPO 
5 5 
2 
EPO 
60 23 
0.569 
Non-EPO 
7 3 
3 
EPO 
34 49 
0.616 
Non-EPO 
4 6 
4 
EPO 
41 42 
0.616 
Non-EPO 
5 5 
5 
EPO 
41 42 
0.412 
Non-EPO 
4 6 
6 
EPO 
57 26 
0.621 
Non-EPO 
7 3 
7 
EPO 
41 42 
0.186 
Non-EPO 
7 3 
8 EPO 
42 41 
0.616 
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The duration of hemodialysis also plays an important role in the quality of life of patients. 
Patients who had received hemodialysis for a long time tended to have a high score of quality of life. 
At the beginning of hemodialysis, patients respond as if they have not accepted the loss of their kidney 
function yet. They tend to be angry with the situation, feel sad with the state of their current life, and 
require a prolonged adjustment to the new environment. As for the patients who have been on 
hemodialysis for a long time, they have a good quality of life because they are psychologically more 
prepared and have been able to adapt to the conditions they must live in, received more health 
education, and established better social relations with health workers (Astuti, 2015). 
 
Research limitations 
In this study, the data are limited to Hb levels and red blood cell profiles obtained from the 
medical records of patients who have received either EPO or non-EPO therapy. Due to time limitation 
and researcher’s knowledge, the analysis excludes many other factors that can influence the increase 
of Hb level and red blood cells in CKD patients, such as food, compliance, and the consumption of 
drugs other than the ones administered in the hemodialysis ward. Therefore, further research involving 
a wider dataset of the determinants of Hb levels and red blood cells becomes necessary.  
 
CONCLUSIONS 
The results showed that the Hb levels and erythrocyte indices in the EPO and non-EPO therapy 
groups were insignificantly different. Also, there was no significant difference between the EPO and 
non-EPO therapy groups regarding the quality of life of CKD patients on hemodialysis. 
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